
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
GLOBAL TRIALS : New Survey Baselines Global Sites Keys to Success in China Budgeting for Global Trials European Ethics Committees CRO/SPONSOR : Think About the Drug Label First LABS : 3-Prong Model for CV Safety Immune Response Screens a Necessity eCLINICAL : ePRO?s Tipping Point Also in this issue : FDA?s New Risk Approach to Site Inspections, EMA Speaks to Stem Cell Research, Mother Lode of Latent Research Data
over 16 years ago
Biosimilars Make Headwayover 16 years ago
Business and News Update June 2010over 16 years ago
Electronic Integration Costsover 16 years ago
Strategic Immunogenicity Testingover 16 years ago
ePRO vs. Paperover 16 years ago
Today's Global Site Landscapeover 16 years ago
Changing Medicines, Changing Rulesover 16 years ago
Ethics Diversity Persistsover 16 years ago
Mastering Currency Fluctuationover 16 years ago
Just Breathe: COPD, Asthma Future





